Location History:
- Villiers-Sous-Grez, FR (1999)
- Montrouge, FR (2004 - 2010)
Company Filing History:
5 out of 869 
1 out of 1 Years Active: 1999-2010
Title: Pierre Perrin: Innovator in Chimeric Lyssavirus Research
Introduction
Pierre Perrin is a notable inventor based in Montrouge, France. He has made significant contributions to the field of immunology, particularly through his work on chimeric lyssavirus nucleic acids and polypeptides. With a total of 5 patents, Perrin's innovations are paving the way for advancements in DNA vaccination.
Latest Patents
One of Perrin's latest patents focuses on chimeric lyssavirus nucleic acids and polypeptides. This invention provides chimeric nucleic acids, preferably contained on an expression vector, that encode chimeric immunogenic polypeptides. The nucleic acids encode at least site III of a lyssavirus glycoprotein, which has been found to improve the immunogenicity of lyssavirus epitopes for protection from rabies. The chimeric nucleic acids and proteins can also contain antigenic determinants for epitopes other than those of lyssavirus. Thus, the invention provides chimeric nucleic acids and polypeptides that elicit a strong immune response to multiple antigens. The methods of this invention permit DNA vaccination without the need to supply multiple antigens on separate DNA molecules.
Career Highlights
Throughout his career, Pierre Perrin has worked with esteemed organizations such as Institut Pasteur and Biovectors Therapeutics S.A. His work has been instrumental in advancing the understanding of immunogenic responses and developing innovative solutions for vaccination.
Collaborations
Perrin has collaborated with notable colleagues, including Yves Jacob and Chokri Bahloul. These partnerships have contributed to the success of his research and the development of his patents.
Conclusion
Pierre Perrin's contributions to the field of immunology through his innovative patents on chimeric lyssavirus nucleic acids and polypeptides highlight his role as a leading inventor. His work continues to influence the future of DNA vaccination and immunogenic research.